BIO89-100-122 - A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of BIO89-100 in Subjects with Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)
Administered By
Awarded By
Contributors
- Bashir, Mustafa Shadi Rifaat Principal Investigator
Start/End
- September 17, 2021 - September 17, 2023